The ScoliScore™ AIS Prognostic Test


The ScoliScore™ AIS Prognostic Test was developed by Axial Biotech, Inc. and is co-distributed by DePuy Spine and Smith & Nephew. This test is a "clinically validated, multi-gene test that provides a qualitative and quantitative assessment of the likelihood of spinal curve progression for patients who have been diagnosed with Adolescent Idiopathic Scoliosis" (ScoliScore website). Both Dr. Mardjetko and Dr. Kramer participated in the clinical research phases of this genetics test and are continuing to utilize the test to make clinical decisions.

The test involves giving a sample of saliva, which is sent to the Axial Biotech lab for processing. A report is generated with a low, medium, or high risk score. This score predicts the likelihood of the scoliosis progressing to a more severe curve. This test allows the physician to make more personalized decisions on treatment plans.

Since this test is no longer in the research phases your insurance will be billed, but Axial Biotech, Inc. is doing everything possible to help you with billing and reimbursement. Please refer to their SHARP program website for more information.


Inclusion Criteria:

  • A primary diagnosis of AIS
  • Between the ages of 9 and 13 years old
  • A mild scoliosis curve (defined as <25°)
  • Of Caucasian ethnicity (North American, South American, European, Eastern European, Middle Eastern)